Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BC-DXI-843 是特异性 AIMP2-DX2抑制剂(IC50:0.92 μM),比作用于 AIMP2 (IC50 <100 μM) 选择性高 100 倍以上。它具有用于 AIMP2-DX2 肺癌的研究潜力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 362 | 现货 | ||
2 mg | ¥ 536 | 现货 | ||
5 mg | ¥ 898 | 现货 | ||
10 mg | ¥ 1,520 | 现货 | ||
25 mg | ¥ 2,830 | 现货 | ||
50 mg | ¥ 4,180 | 现货 | ||
100 mg | ¥ 5,990 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,250 | 现货 |
产品描述 | BC-DXI-843 is inhibitor of AIMP2-DX2, and is potential for development of novel therapeutics targeting AIMP2-DX2 in lung cancer. |
靶点活性 | AIMP2-DX2:0.92 μM (IC50), AIMP2:IC50 >100 μM |
体外活性 | Optimization of hit BC-DXI-04 (IC50 = 40.1 μM) provided new potent sulfonamide based AIMP2-DX2 inhibitors.?Among these, BC-DXI-843 showed improved inhibition against AIMP2-DX2 (IC50 = 0.92 μM) with more than 100-fold selectivity over AIMP2 in a luciferase assay.?Several binding assays indicated that this compound effectively induces cancer cell apoptosis by specifically interrupting the interaction between DX2 and HSP70, which leads to the degradation of DX2 via Siah1-mediated ubiquitination. |
体内活性 | BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer. |
分子量 | 546.66 |
分子式 | C28H26N4O4S2 |
CAS No. | 2421117-98-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 245 mg/mL (448.18 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8293 mL | 9.1465 mL | 18.2929 mL | 45.7323 mL |
5 mM | 0.3659 mL | 1.8293 mL | 3.6586 mL | 9.1465 mL | |
10 mM | 0.1829 mL | 0.9146 mL | 1.8293 mL | 4.5732 mL | |
20 mM | 0.0915 mL | 0.4573 mL | 0.9146 mL | 2.2866 mL | |
50 mM | 0.0366 mL | 0.1829 mL | 0.3659 mL | 0.9146 mL | |
100 mM | 0.0183 mL | 0.0915 mL | 0.1829 mL | 0.4573 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BC-DXI-843 2421117-98-6 Others Inhibitor BC-DXI 843 lung A549 BC-DXI843 BCDXI843 AIMP2-DX2 cancer inhibit BC DXI 843 inhibitor